Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive Biomarkers of Clinical Response to Lenvatinib Therapy in Hepatocellular CarcinomaMakoto Chuma, Shin Maeda, Masanori Atsukawa et al.|Cancers|2020Cited by 54
Direct-acting antivirals improve survival and recurrence rates after treatment of hepatocellular carcinoma within the Milan criteriaHironori Ochi, Kouji Joko, Atsushi Hiraoka et al.|Journal of Gastroenterology|2020Cited by 45
Lenvatinib-induced thyroid abnormalities in unresectable hepatocellular carcinomaYohei Koizumi, Yoichi Hiasa, Masashi Hirooka et al.|Endocrine Journal|2019Cited by 39
Using ALBI score at the start of sorafenib treatment to predict regorafenib treatment candidates in patients with hepatocellular carcinomaAtsushi Yukimoto, Yoichi Hiasa, Masashi Hirooka et al.|Japanese Journal of Clinical Oncology|2018Cited by 35